Pharmaceutical Intermediate Mirabegron Powder Mirabegron

• Customization: Available
• CAS No.: 223673-61-8
• Formula: C21h24n4o2s
• Model NO.: QS-Mirabegron
• EINECS: 800-126-3
• Packaging Material: Negotiable
• Storage Method: Normal
• Shelf Life: >12 Months
• Nutrient Composition: Mirabegron
• Resource: Mirabegron
• The content of active substances: >99%
• Product Name: Mirabegron
• Name: Mirabegron Powder
• Appearance: White Powder
• Colour: White
• Grade: Veterinary Grade
• Assay: >99%
• Application: API
• Specific: COA
• Test Method: HPLC
• Density: 1.313
• Mf: C21h24n4o2s
• MW: 396.5059
• Melting Point: 138-140c
• Boiling Point: 690c
• Accurate Mass: 396.16199719
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS-Mirabegron
• Origin: Xian
• Production Capacity: 1000kg/Month

Product Description

Pharmaceutical Intermediate Mirabegron Powder Mirabegron 
 

Product Description

 

Product Details

Product Name	Mirabegron
Appearance	Mirabegron Powder
Assay	>99%
MW	396.5059
MF	C21H24N4O2S
Melting point	138-140C
Boiling point	690C

Overactive Bladder: Mirabegron is prescribed for adults with symptoms of OAB, such as urgency, urinary frequency, and urge incontinence.
Urinary Incontinence: It can be used to manage urge incontinence, a type of incontinence where an urgent need to urinate leads to involuntary loss of urine.
Combination Therapy: Mirabegron may be used in combination with other therapies, such as anticholinergics, for patients who do not respond adequately to monotherapy.

Application&Function

1. β3-Adrenoceptor Agonist Action: Mirabegron selectively binds to and activates β3-adrenoceptors in the bladder, resulting in smooth muscle relaxation and decreased contractility.
2. Increase in Bladder Capacity: By relaxing the detrusor muscle, mirabegron increases bladder capacity and reduces the frequency of urination and urgency symptoms.
3. Improvement in Quality of Life: Effective management of OAB symptoms with mirabegron can lead to significant improvements in patients' quality of life, reducing the impact of urinary symptoms on daily activities.

Specification